Akari Therapeutics: director Samir Patel received 53,536 shares

What happened Samir Patel, director, received awards and option grants according to the Form 4. The filing reports a grant of 6,300 ADSs at $7.90 on Aug 18, 2026 (value $49,764) and a grant of 2,236 ADSs at $7.90 on Oct 5, 2026 (value $17,662). The filing also reports grants of options to purchase 30,000 ADSs and 15,000 ADSs on Aug 18, 2026 at an exercise price of $0.00 (derivative awards).

Key details

• Transaction dates and prices: Aug 18, 2026 — 6,300 ADSs at $7.90 ($49,764) and option grants for 30,000 ADSs and 15,000 ADSs at $0.00; Oct 5, 2026 — 2,236 ADSs at $7.90 ($17,662).
• Shares owned after the transactions: the filing does not state the amount of beneficial ownership following these transactions.
• Footnotes the filing includes:
  • The ADSs represent restricted stock units (RSUs), with each RSU representing the right to receive 80,000 ordinary shares (par value $0.000000005 per share). The RSU grants are subject to forfeiture if shareholder approval to increase shares reserved under the equity plan ("Shareholder Approval") is not obtained. (F1, F2)
  • One RSU award was granted in lieu of accrued but unpaid cash retainers payable to non-executive directors. (F3)
  • The 30,000-ADS option vests 4.17% for each one-month anniversary of Aug 18, 2026 that has elapsed before Shareholder Approval, with the remainder vesting in equal monthly installments after Shareholder Approval until fully vested on the two-year anniversary of Aug 18, 2026, subject to continued service. (F4)
  • The 15,000-ADS option vests 8.33% on the date of Shareholder Approval plus 8.33% for each one-month anniversary of Aug 18, 2026 that has elapsed before Shareholder Approval, with the remainder vesting in equal monthly installments after Shareholder Approval until fully vested on the one-year anniversary of Aug 18, 2026, subject to continued service. (F5)
• Filing date and timing: the Form 4 was filed Oct 16, 2026; the reported transactions occurred on Aug 18, 2026 and Oct 5, 2026 (the filing date is after those transaction dates).

Why it may matter

• These were award and option grants rather than open-market purchases or sales; the options are subject to vesting schedules and shareholder approval conditions described above.
• One RSU award was granted in lieu of accrued but unpaid cash retainers, per the filing.
• This filing does not show why the insider traded or why the company acted.